Cost-Effectiveness of Juluca (dolutegravir/rilpivirine) for Human Immunodeficiency Virus (HIV-1) Infection Treatment in Virologically Suppressed Adults in Taiwan

Cost-Effectiveness of Juluca (dolutegravir/rilpivirine) for Human Immunodeficiency Virus (HIV-1) Infection Treatment in Virologically Suppressed Adults in Taiwan

Objectives: Although the efficacy of traditional 3-drug regimens for the treatment of HIV is well established, tolerability and toxicity concerns remain. New 2-drug regimens such as Juluca (dolutegravir [DTG]/rilpivirine [RPV]) offer noninferior efficacy versus 3-drug regimens (SWORD-1 and SWORD-2 s...

Full description

Bibliographic Details
Main Authors: Anderson, S.-J (Author), Hsu, C.-Y (Author), Ko, N.-Y (Author), Lopes, S. (Author), Ou, H.-T (Author), Yang, C.-T (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2021
Subjects:
abacavir plus dolutegravir plus lamivudine
adult
Adult
anti human immunodeficiency virus agent
Anti-HIV Agents
Article
cardiovascular disease
CD4 lymphocyte count
chronic kidney failure
clinical outcome
cobicistat plus elvitegravir plus emtricitabine plus tenofovir alafenamide
cost benefit analysis
cost control
cost effectiveness analysis
Cost-Benefit Analysis
cost-effectiveness
data base
decision tree
dolutegravir
dolutegravir plus rilpivirine
dolutegravir, rilpivirine drug combination
drug combination
Drug Combinations
drug cost
drug efficacy
drug safety
drug tolerability
emtricitabine plus rilpivirine plus tenofovir disoproxil
fracture
fused heterocyclic rings
gross national product
health care cost
Heterocyclic Compounds, 3-Ring
HIV
HIV Infections
human
Human immunodeficiency virus 1 infection
Human immunodeficiency virus infection
Humans
Markov state model
national health insurance
quality adjusted life year
rilpivirine
Rilpivirine
Taiwan
viral suppression
virus load
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items